BR0312283A - Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf - Google Patents
Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegfInfo
- Publication number
- BR0312283A BR0312283A BR0312283-2A BR0312283A BR0312283A BR 0312283 A BR0312283 A BR 0312283A BR 0312283 A BR0312283 A BR 0312283A BR 0312283 A BR0312283 A BR 0312283A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- agent
- vegf activity
- reducing agent
- activity reducing
- Prior art date
Links
- 229940100198 alkylating agent Drugs 0.000 title abstract 2
- 239000002168 alkylating agent Substances 0.000 title abstract 2
- 239000003638 chemical reducing agent Substances 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39258902P | 2002-06-28 | 2002-06-28 | |
| PCT/EP2003/006848 WO2004002485A1 (en) | 2002-06-28 | 2003-06-27 | Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0312283A true BR0312283A (pt) | 2005-04-12 |
Family
ID=30000898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0312283-2A BR0312283A (pt) | 2002-06-28 | 2003-06-27 | Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7754716B2 (https=) |
| EP (1) | EP1545527A1 (https=) |
| JP (1) | JP2005531622A (https=) |
| CN (1) | CN100355423C (https=) |
| AU (1) | AU2003249895A1 (https=) |
| BR (1) | BR0312283A (https=) |
| CA (1) | CA2490130A1 (https=) |
| WO (1) | WO2004002485A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1922311A2 (en) | 2005-09-09 | 2008-05-21 | Brystol-Myers Squibb Company | Acyclic ikur inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5939098A (en) * | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| ATE369894T1 (de) * | 2000-11-22 | 2007-09-15 | Novartis Pharma Gmbh | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
| RU2003126913A (ru) * | 2001-02-02 | 2005-03-10 | Шеринг Корпорейшн (US) | 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс |
| GB0111078D0 (en) | 2001-05-04 | 2001-06-27 | Novartis Ag | Organic compounds |
| JP2005505595A (ja) * | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
-
2003
- 2003-06-27 CN CNB038149222A patent/CN100355423C/zh not_active Expired - Fee Related
- 2003-06-27 BR BR0312283-2A patent/BR0312283A/pt not_active IP Right Cessation
- 2003-06-27 CA CA002490130A patent/CA2490130A1/en not_active Abandoned
- 2003-06-27 EP EP03761547A patent/EP1545527A1/en not_active Withdrawn
- 2003-06-27 US US10/518,989 patent/US7754716B2/en not_active Expired - Fee Related
- 2003-06-27 AU AU2003249895A patent/AU2003249895A1/en not_active Abandoned
- 2003-06-27 JP JP2004516730A patent/JP2005531622A/ja active Pending
- 2003-06-27 WO PCT/EP2003/006848 patent/WO2004002485A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005531622A (ja) | 2005-10-20 |
| US20060211674A1 (en) | 2006-09-21 |
| CN1662239A (zh) | 2005-08-31 |
| AU2003249895A1 (en) | 2004-01-19 |
| EP1545527A1 (en) | 2005-06-29 |
| CA2490130A1 (en) | 2004-01-08 |
| CN100355423C (zh) | 2007-12-19 |
| US7754716B2 (en) | 2010-07-13 |
| WO2004002485A1 (en) | 2004-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
| Kaji et al. | Effect of ultrahigh‐dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double‐blind controlled study | |
| BR0317747A (pt) | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave | |
| BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| SG166775A1 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
| BR0316004A (pt) | Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina | |
| BR0316157A (pt) | Derivados de 4-amino-5-fenil-7-ciclohexil-pirrolo[2,3-d]pirimidina | |
| ATE332136T1 (de) | Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| TW200510392A (en) | Chemical compounds | |
| MXPA05003253A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos. | |
| BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
| IL151628A0 (en) | Combination therapies with vascular damaging activity | |
| BRPI0416275A (pt) | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada | |
| EA200602047A1 (ru) | Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| DE60333754D1 (de) | Epothilone enthaltende kombinationen und deren pharmazeutische verwendungen | |
| BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
| EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
| CA2385755A1 (en) | Prevention of colorectal cancer | |
| MXPA04001912A (es) | Aminobenzofenonas novedosas. | |
| BR0312283A (pt) | Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf | |
| EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE | |
| BR0316029A (pt) | Combinação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 8A. ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011. |